A cancer drug which was approved by the European Commission in 2013 has finally been recommended for use on the National Health Service (NHS) in England.
US biotech firm Incyte Corp (Nasdaq: INCY) says that the National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending Iclusig (ponatinib) for chronic myeloid leukemia (CML) in adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation.
"Together with the CML community, we have worked very hard over the last four years to encourage NICE to reconsider its original evaluation"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze